Immatics

Technology

Immatics has established two proprietary cancer cell target and TCR discovery platforms: XPRESIDENT^® and XCEPTOR^®. The company’s thesis is that for the development of safe and effective TCR-based immunotherapies, two fundamental steps are required (i) picking a true cancer target that is naturally and specifically expressed at significant levels on the tumor, and (ii) developing the right, potent TCR that specifically recognizes the selected cancer cell target with minimal or no cross-reactivity with healthy tissues.

Identifying
Novel Cancer Targets

Based on the unique interplay between Immatics’ target and TCR discovery platforms XPRESIDENT^® and XCEPTOR^®, we have the capability to identify and engineer the right T cell receptors with the desired affinity and specificity. These two technology platforms are the foundation for Immatics’ product pipeline and our leading position in the field of TCR-based immunotherapies. Over time Immatics has published its discoveries in multiple peer-reviewed, high-impact publications including Nature, Nature Medicine, Nature Biotechnology, Nature Communications and Lancet Oncology.